Lisuride hydrogen maleate: an ergoline with beta-adrenergic antagonist activity.
Lisuride hydrogen maleate is identified as a potent beta-adrenergic antagonist using a hormone-sensitive adenylate cyclase system and [3H]dihydroalprenolol binding in cell free homogenates of rabbit cerebellum. Lisuride and two other ergolines, lergotrile and bromocriptine, and the phenothiazine, fluphenazine, all interact with spiroperidol binding sites (dopamine receptors) in the anterior pituitary; however, among these compounds lisuride is unique in its ability to antagonize the beta-adrenoceptor.
D000262:Adenylyl Cyclases / Q000378:metabolism; D000319:Adrenergic beta-Antagonists; D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D002531:Cerebellum / Q000187:drug effects* / Q000201:enzymology; D004082:Dihydroalprenolol / Q000494:pharmacology; D004873:Ergolines / Q000494:pharmacology*; D007545:Isoproterenol / Q000494:pharmacology; D008090:Lisuride / Q000494:pharmacology*; D011817:Rabbits; D013134:Spiperone / Q000378:metabolism
D000319:Adrenergic beta-Antagonists; D004873:Ergolines; D013134:Spiperone; D004082:Dihydroalprenolol; D008090:Lisuride; D000262:Adenylyl Cyclases; D007545:Isoproterenol